The next "Ozempic" like product in aesthetics? Findell Capital flags $ESTA:US as a multibagger

In June, SumZero CEO Divya Narendra sat down with Brian Finn, the top-ranked healthcare analyst on SumZero platform and CIO and Founder of Findell Capital. In this episode, we delve into Establishment Labs (ESTA:US), a Costa Rican-based breast implant manufacturer that's about to make waves in the U.S. market with its groundbreaking products, Motiva and MiaFemTech. Discover why ESTA's innovative implants are considered best-in-class for safety and efficacy, the historical context of breast implants, and why there's significant investor interest now. Learn more about the company's market position, growth potential, and future plans, including the anticipated FDA approval and expansion into the U.S. market. Perfect for anyone interested in emerging medtech investment opportunities.

That full discussion is available here.

Brian is a long-time SumZero member, having shared more than 20 of his highest conviction theses with the community over the years. His average idea on SumZero has outperformed it's respective benchmark by more than 30%, to date.